Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series - 24/08/11
Correspondence and reprint requests to: Mark G. Lebwohl, MD, Chairman, Department of Dermatology, Mount Sinai Medical Center, 1 Gustave L. Levy Place, Box 1048, New York, NY 10029.New York, New York
Résumé |
Background |
Mycosis fungoides, the most common form of cutaneous T-cell lymphoma, often presents as chronic eczematous or psoriasiform patches and plaques that can be resistant to a variety of single-agent treatment modalities, necessitating combination therapy.
Objective |
To evaluate the efficacy of combination therapy with bexarotene and psoralen plus ultraviolet A (PUVA) in treating patients with cutaneous T-cell lymphoma (CTCL) that recurred following monotherapy with multiple agents, including electron-beam irradiation, interferon, PUVA, and topical steroids. This was done by retrospective chart review.
Methods |
Retrospective chart review analysis of eight patients with CTCL ranging from stage Ia to IIb who failed multiple single-agent treatment regimens treated with low-dose oral bexarotene and PUVA combination therapy.
Results |
We noted an initial response in all eight patients and complete remission in five of the patients treated, with pruritus being the most common adverse event.
Conclusion |
In view of its good safety profile, combination therapy with bexarotene and PUVA may be considered for patients with treatment resistant CTCL refractory to monotherapy.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. The authors have no conflict of interest to disclose. |
Vol 51 - N° 4
P. 570-573 - octobre 2004 Retour au numéro
Article précédent
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment
- Richard G. Langley, Charles N. Ellis
- Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: An open trial evaluating 9 consecutive patients
- Alexander Kreuter, Thilo Gambichler, Frank Breuckmann, Falk G. Bechara, Sebastian Rotterdam, Markus Stücker, Peter Altmeyer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?